Negro-Vilar A - Search Results

1

Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.

Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M, Pereira JR, Temperley G, Negro-Vilar R, Rahal S, Zhang JK, Negro-Vilar A, Dziewanowska ZE. Ramlau R, et al. Among authors: negro vilar a. J Clin Oncol. 2008 Apr 10;26(11):1886-92. doi: 10.1200/JCO.2007.12.2614. J Clin Oncol. 2008. PMID: 18398154 Clinical Trial.

2

Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.

Blumenschein GR Jr, Khuri FR, von Pawel J, Gatzemeier U, Miller WH Jr, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A. Blumenschein GR Jr, et al. Among authors: negro vilar a. J Clin Oncol. 2008 Apr 10;26(11):1879-85. doi: 10.1200/JCO.2007.12.2689. J Clin Oncol. 2008. PMID: 18398153 Clinical Trial.

3

Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer.

Luo W, Schork NJ, Marschke KB, Ng SC, Hermann TW, Zhang J, Sanders JM, Tooker P, Malo N, Zapala MA, Dziewanowska ZE, Negro-Vilar A, Meglasson MD. Luo W, et al. Among authors: negro vilar a. Anticancer Res. 2011 Jun;31(6):2303-11. Anticancer Res. 2011. PMID: 21737656

4

A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.

Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, Nugent WC, Hermann T, Negro-Vilar A, Rigas JR, Dmitrovsky E. Dragnev KH, et al. Clin Cancer Res. 2007 Mar 15;13(6):1794-800. doi: 10.1158/1078-0432.CCR-06-1836. Clin Cancer Res. 2007. PMID: 17363535 Clinical Trial.

5

A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.

Yen WC, Corpuz MR, Prudente RY, Cooke TA, Bissonnette RP, Negro-Vilar A, Lamph WW. Yen WC, et al. Clin Cancer Res. 2004 Dec 15;10(24):8656-64. doi: 10.1158/1078-0432.CCR-04-0979. Clin Cancer Res. 2004. PMID: 15623650

6

Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.

Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Prince HM, et al. Among authors: negro vilar a. J Clin Oncol. 2010 Apr 10;28(11):1870-7. doi: 10.1200/JCO.2009.26.2386. Epub 2010 Mar 8. J Clin Oncol. 2010. PMID: 20212249 Clinical Trial.

7

The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.

Hermann TW, Yen WC, Tooker P, Fan B, Roegner K, Negro-Vilar A, Lamph WW, Bissonnette RP. Hermann TW, et al. Lung Cancer. 2005 Oct;50(1):9-18. doi: 10.1016/j.lungcan.2005.05.008. Lung Cancer. 2005. PMID: 15993980

8

Sleep improves when patients with chronic OA pain are managed with morning dosing of once a day extended-release morphine sulfate (AVINZA): findings from a pilot study.

Rosenthal M, Moore P, Groves E, Iwan T, Schlosser LG, Dziewanowska Z, Negro-Vilar A. Rosenthal M, et al. Among authors: negro vilar a. J Opioid Manag. 2007 May-Jun;3(3):145-54. doi: 10.5055/jom.2007.0052. J Opioid Manag. 2007. PMID: 18027540 Clinical Trial.

9

Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.

Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW. Tooker P, et al. Cancer Res. 2007 May 1;67(9):4425-33. doi: 10.1158/0008-5472.CAN-06-4495. Cancer Res. 2007. PMID: 17483357

10

Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator.

van Oeveren A, Motamedi M, Mani NS, Marschke KB, López FJ, Schrader WT, Negro-Vilar A, Zhi L. van Oeveren A, et al. J Med Chem. 2006 Oct 19;49(21):6143-6. doi: 10.1021/jm060792t. J Med Chem. 2006. PMID: 17034117

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

211 results

Search Page

Filters